Fig. 6. Tumor-intrinsic YTHDF1 deficiency enhances ICI therapy responses in vivo.

A The protein expression of surface PD-L1 was analyzed by flow cytometry and is shown as the mean fluorescence intensity (MFI). n = 3 biologically independent samples per group. Two-tailed unpaired Student’s t-test. Data are presented as mean values ± SD. B The t-SNE plot of Pdcd1 and Ctla4 in CD8⁺ T cells. C Tumor growth curves of WT and KO tumors. Mice were intraperitoneally treated with 200 µg anti-PD-L1 or 200 µg anti-CTLA4 on days 7, 9 and 11 after tumor inoculation. A rat immunoglobulin G (IgG) isotype antibody was applied as a control. Two-way ANOVA with Tukey’s multiple comparison test. Data are presented as mean values ± SD. The statistical comparisons among these groups were listed as follows: WT + IgG vs KO + IgG, p = 0.0001; WT + IgG vs WT + PD-L1, p = 0.0084; WT + IgG vs WT + CTLA4, p = 0.0004; WT + IgG vs KO + PD-L1, p = 0.0001; WT + IgG vs KO + CTLA4, p = 0.0001; KO + IgG vs KO + PD-L1, p = 0.0223; KO + IgG vs KO + CTLA4, p = 0.020; WT + CTLA4 vs KO + CTLA4, p = 0.0315; WT + PD-L1 vs KO + PD-L1, p = 0.0069. D Individual tumor growth curves and percentages of mice with complete tumor rejection. E Kaplan–Meier curves for WT and KO tumor-bearing C57BL/6J mice treated with an IgG isotype, anti-PD-L1 (200 µg) or anti-CTLA4 antibody (200 µg). Tumor volumes exceeding 1500 mm³ were considered events (n = 8 biologically independent animals per group). Two-tailed log-rank (Mantel–Cox) test. F Tumor growth curves of mice rechallenged with WT B16/F10. The results are representative of two independent experiments. Two-way ANOVA with Tukey’s multiple comparison test. Data are presented as mean values ± SD. Source data are provided as a Source Data file.